UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 3) 1

GTx, Inc.
(Name of Issuer)
Common Stock, \$0.001 par value per share
(Title of Class of Securities)
40052B 20 7
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPORTING PERSON			
	Biotechnology Value Fund, L.P.			
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) 🗆	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	5 1			
AND OF SE	Delaware	COVE VICENIC POLITIP		
NUMBER OF	5	SOLE VOTING POWER		
SHARES BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH	0	SHARED VOTING POWER		
REPORTING		1,029,241 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
121001 ((1111	,	SOLE DISTOSITIVE FOWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		1,029,241 (1)		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,029,241 (1)			
10	CHECK BOX IF THE	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	4.70/ (4)			
10	4.7% (1)	INC DEDCOM		
12	TYPE OF REPORT	ING PERSON		
	PN			
	I I'I			

(1) Includes 514,614 shares of Common Stock currently issuable upon the exercise of certain Warrants (defined below) held by BVF.

1	NAME OF REPORTING PERSON			
	Biotechnology Value Fund II, L.P.			
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHID OD	DI ACE OF OPCANIZATION		
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH		F 40 004 (4)		
REPORTING PERSON WITH		540,904 (1) SOLE DISPOSITIVE POWER		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		540,904 (1)		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	540,904 (1)			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	DERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)		
11	TERCENT OF CENSORER RESERVED BY AMOUNT IN ROW (3)			
	2.5% (1)			
12	TYPE OF REPORT	TING PERSON	-	
	PN			

(1) Includes 266,667 Shares of Common Stock currently issuable upon the exercise of certain Warrants (defined below) held by BVF 2.

<u> </u>	+			
1	NAME OF REPORTING PERSON			
	Biotechnology Value Trading Fund OS LP			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)			
			(b) □	
3	SEC USE ONLY			
3	SEC OSE OINLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	-	
	Cayman Isla			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	6	0 shares		
EACH	б	SHARED VOTING POWER		
REPORTING		65,774		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		CE FILA		
9	ACCDECATE AM	65,774 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	65,774			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
		•		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	T			
12	Less than 1% TYPE OF REPORT			
12	I I PE OF KEPORI	ING PERSON		
	PN			
	1			

	+			
1	NAME OF REPORTING PERSON			
	BVF Partners OS Ltd.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)			
			(b) □	
3	CEC LICE ONLY			
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	-	
	Cayman Isla			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	<u> </u>	0 shares		
EACH	6	SHARED VOTING POWER		
REPORTING		65,774		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		C5 554		
9	ACCDECATE AM	65,774 IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGATE AM	IOUNI DENEFICIALLI OWNED DI EACH REPORTING PERSON		
	65,774			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
		•		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	T (1- 40	,		
12	Less than 19 TYPE OF REPORT			
12	I I PE OF KEPORI	THING PERSON		
	CO			
İ				

1	NAME OF REPORTING PERSON			
	BVF Partners L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠			
2	CHECK THE APPROI	(a) ⊠		
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OR PLA	ACE OF ORGANIZATION		
	D 1			
NUMBER OF	Delaware 5	SOLE VOTING POWER		
SHARES	J	SOLE VOTING FOWER		
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		2,218,514 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		2,218,514 (1)		
9	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,218,514 (1)			
10		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
		· ,		
11	PERCENT OF CLASS	S REPRESENTED BY AMOUNT IN ROW (9)		
	9.8% (1)			
12	TYPE OF REPORTING	G PERSON		
	DN ΙΔ			

(1) Includes 1,111,081 shares of Common Stock currently issuable upon the exercise of certain Warrants (defined below) held by BVF, BVF2, and the Partners Managed Accounts (defined below).

1	NAME OF REPORTING PERSON			
	BVF Inc.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [a]			
2	CHECK THE AFFRO	(a) ⊠ (b) □		
			(6) =	
3	SEC USE ONLY			
4	CITIZENSHIP OR PI	ACE OF ORGANIZATION		
7	CITIZENSIIII OKTE	NOL OF OROTHVETHOR		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH		SIMILE FORMOTOWER		
REPORTING		2,218,514 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		2,218,514 (1)		
9	AGGREGATE AMOU	JNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,218,514 (1)			
10		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLASS	S REPRESENTED BY AMOUNT IN ROW (9)		
	9.8% (1)			
12	TYPE OF REPORTIN	G PERSON		
	CO			

(1) Includes 1,111,081 shares of Common Stock currently issuable upon the exercise of certain Warrants (defined below) held by BVF, BVF2, and the Partners Managed Accounts (defined below).

1	NAME OF REPORTING PERSON			
	Mark N. Lan			
2	CHECK THE APPE	(a) 🗵		
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	United States			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH		2 240 544 (4)		
REPORTING PERSON WITH		2,218,514 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
	0	SHARED DISPOSITIVE POWER		
		2,218,514 (1)		
9	ACCRECATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
3	71001tE0711E71W	OUT BEITH CHILD DI ENGILLE ORTING LEROON		
	2,218,514 (1)			
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
		(c)		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
		· · ·		
	9.8% (1)			
12	TYPE OF REPORT	TNG PERSON		
	IN			

(1) Includes 1,111,081 shares of Common Stock currently issuable upon the exercise of certain Warrants (defined below) held by BVF, BVF2, and the Partners Managed Accounts (defined below).

Item 1(a). Name of Issuer:

GTx, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

175 Toyota Plaza, 7th Floor Memphis, Tennessee 38103

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners L.P. ("Partners") 1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Inc.

1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 1 Sansome Street, 30th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share (the "Common Stock")

Item 2(e). CUSIP Number:

40052B 20 7

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

/x/ Not applicable.

- (a) // Broker or dealer registered under Section 15 of the Exchange Act.
- (b) // Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) // Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) // Investment company registered under Section 8 of the Investment Company Act.
- (e) // An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f) // An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) // A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) // A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) // A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
- (k) // Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), pth type of institution:

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on December 31, 2017, the Reporting Persons held warrants exercisable for an aggregate of 1,111,081 shares of Common Stock (the "Warrants"). The Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act"), more than 9.99% of the number of shares of Common Stock then issued and outstanding. In providing beneficial ownership described herein, the Reporting Persons have assumed that 514,614 Warrants held by BVF, 266,667 Warrants held by BVF2 and 329,800 Warrants held by the Partners Managed Accounts (defined below) would be exercised to acquire 1,111,081 shares of Common Stock underlying the Warrants.

As of the close of business on December 31, 2017 (i) BVF beneficially owned 1,029,241 shares of Common Stock, including 514,614 shares of Common Stock issuable upon the exercise of Warrants held by it, (ii) BVF2 beneficially owned 540,904 shares of Common Stock, including 266,667 shares of Common Stock issuable upon the exercise of Warrants and (iii) Trading Fund OS beneficially owned 65,774 shares of Common Stock.

Partners OS as the general partner of Trading Fund OS may be deemed to beneficially own the 65,774 shares of Common Stock beneficially owned by Trading Fund OS.

Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,218,514 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners managed accounts (the "Partners Managed Accounts"), including 582,595 shares of Common Stock held in the Partners Managed Accounts, which includes 329,800 shares of Common Stock issuable upon the exercise of Warrants held within the Partners Managed Accounts.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,218,514 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,218,514 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on a denominator that is the sum of: (i) 21,541,909 shares of Common Stock outstanding as of December 15, 2017, which is the total number of Shares outstanding as reported in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 22, 2017 and (b) certain or all of the 1,111,081 shares of Common Stock that may be acquired upon the conversion of certain or all Warrants, as applicable.

As of the close of business on December 31, 2017 (i) BVF beneficially owned approximately 4.7% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 2.5% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock (iv) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.8% of the outstanding shares of Common Stock (approximately 2.7% of which is held in the Partners Managed Accounts).

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to Amendment No. 1 to the Schedule 13G filed with the Securities and Exchange Commission on February 16, 2016.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2018

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President